Chapter 1 Gender Differences in Pharmacological Response

International Review of Neurobiology

Volumn 83, Issue , 2008, Pages 1-10

  Anderson, Gail D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450;

BODY WEIGHT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG HYPERSENSITIVITY; DRUG THERAPY; FEMALE; HUMAN; LIVER DISEASE; LONG QT SYNDROME; MALE; METABOLISM; PHARMACOKINETICS; PHYSIOLOGY; REVIEW; SEXUAL DEVELOPMENT;

BODY WEIGHT; CYTOCHROME P-450 ENZYME SYSTEM; DRUG HYPERSENSITIVITY; DRUG THERAPY; FEMALE; HUMANS; LIVER DISEASES; LONG QT SYNDROME; MALE; PHARMACOKINETICS; SEX CHARACTERISTICS;

EID: 53249086413     PISSN: 00747742     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0074-7742(08)00001-9     Document Type: Review

References (36)

1. Anderson G.D. Sex and racial differences in pharmacological response: Where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics. J. Womens Health (Larchmt) 14 (2005) 19-29
2. Arif H., Buchsbaum R., Weintraub D., Koyfman S., Salas-Humara C., Bazil C.W., Resor Jr. S.R., and Hirsch L.J. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 68 (2007) 1701-1709
3. Buckwalter J.A., and Lappin D.R. The disproportionate impact of chronic arthralgia and arthritis among women. Clin. Orthop. Relat. Res. 372 (2000) 159-168
4. Burchell B., Brierley C.H., and Rance D. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci. 57 (1995) 1819-1831
5. Chen M.L., Lee S.C., Ng M.J., Schuirmann D.J., Lesko L.J., and Williams R.L. Pharmacokinetic analysis of bioequivalence trials: Implications for sex-related issues in clinical pharmacology and biopharmaceutics. Clin. Pharmacol. Ther. 68 (2000) 510-521
6. Cummins C.L., Wu C.Y., and Benet L.Z. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin. Pharmacol. Ther. 72 (2002) 474-489
7. Domecq C., Naranjo C.A., Ruiz I., and Busto U. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int. J. Clin. Pharmacol. Ther. Toxicol. 18 (1980) 362-366
8. Dreifuss F.E., and Langer D.H. Hepatic considerations in the use of antiepileptic drugs. Epilepsia 28 Suppl. 2 (1987) S23-S29
9. Dreifuss F.E., Santilli N., Langer D.H., Sweeney K.P., Moline K.A., and Menander K.B. Valproic acid hepatic fatalities: A retrospective review. Neurology 37 (1987) 379-385
10. Drici M.D., and Clement N. Is gender a risk factor for adverse drug reactions? The example of drug-induced long QT syndrome. Drug Saf. 24 (2001) 575-585
11. Fattinger K., Roos M., Vergeres P., Holenstein C., Kind B., Masche U., Stocker D.N., Braunschweig S., Kullak-Ublick G.A., Galeazzi R.L., Follath F., et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Br. J. Clin. Pharmacol. 49 (2000) 158-167
12. Frezza M., di Padova C., Pozzato G., Terpin M., Baraona E., and Lieber C.S. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N. Engl. J. Med. 322 (1990) 95-99
13. 51Cr-EDTA. Braz. J. Med. Biol. Res. 25 (1992) 129-134
14. Holt V.L., Scholes D., Wicklund K.G., Cushing-Haugen K.L., and Daling J.R. Body mass index, weight, and oral contraceptive failure risk. Obstet. Gynecol. 105 (2005) 46-52
15. Konishi T., Naganuma Y., Hongo K., Murakami M., Yamatani M., and Okada T. Carbamazepine-induced skin rash in children with epilepsy. Eur. J. Pediatr. 152 (1993) 605-608
16. Kramlinger K.G., Phillips K.A., and Post R.M. Rash complicating carbamazepine treatment. J. Clin. Psychopharmacol. 14 (1994) 408-413
17. Liu X.K., Katchman A., Whitfield B.H., Wan G., Janowski E.M., Woosley R.L., and Ebert S.N. In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits. Cardiovasc. Res. 57 (2003) 28-36
18. Makkar R.R., Fromm B.S., Steinman R.T., Meissner M.D., and Lehmann M.H. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 270 (1993) 2590-2597
19. Miller M.A. Gender-based differences in the toxicity of pharmaceuticals-The Food and Drug Administration's perspective. Int. J. Toxicol. 20 (2001) 149-152
20. Mojaverian P., Rocci Jr. M.L., Conner D.P., Abrams W.B., and Vlasses P.H. Effect of food on the absorption of enteric-coated aspirin: Correlation with gastric residence time. Clin. Pharmacol. Ther. 41 (1987) 11-17
21. Overstreet K., Costanza C., Behling C., Hassanin T., and Masliah E. Fatal progressive hepatic necrosis associated with lamotrigine treatment: A case report and literature review. Dig. Dis. Sci. 47 (2002) 1921-1925
22. Park M.A., Matesic D., Markus P.J., and Li J.T. Female sex as a risk factor for penicillin allergy. Ann. Allergy Asthma Immunol. 99 (2007) 54-58
23. Rathore S.S., Curtis J.P., Wang Y., Bristow M.R., and Krumholz H.M. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 289 (2003) 871-878
24. Rathore S.S., Wang Y., and Krumholz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N. Engl. J. Med. 347 (2002) 1403-1411
25. Rider V., and Abdou N.I. Gender differences in autoimmunity: Molecular basis for estrogen effects in systemic lupus erythematosus. Int. Immunopharmacol. 1 (2001) 1009-1024
26. Rodriguez I., Kilborn M.J., Liu X.K., Pezzullo J.C., and Woosley R.L. Drug-induced QT prolongation in women during the menstrual cycle. JAMA 285 (2001) 1322-1326
27. Schuetz E.G., Furuya K.N., and Schuetz J.D. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J. Pharmacol. Exp. Ther. 275 (1995) 1011-1018
28. Schwartz J.B. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin. Pharmacol. Ther. 82 (2007) 87-96
29. Tran C., Knowles S.R., Liu B.A., and Shear N.H. Gender differences in adverse drug reactions. J. Clin. Pharmacol. 38 (1998) 1003-1009
30. Umeh O.C., and Currier J.S. Sex differences in HIV: Natural history, pharmacokinetics, and drug toxicity. Curr. Infect. Dis. Rep. 7 (2005) 73-78
31. Vidaver R.M., Lafleur B., Tong C., Bradshaw R., and Marts S.A. Women subjects in NIH-funded clinical research literature: Lack of progress in both representation and analysis by sex. J. Womens Health Gend. Based Med. 9 (2000) 495-504
32. Whitacre C.C., Reingold S.C., and O'Looney P.A. A gender gap in autoimmunity. Science 283 (1999) 1277-1278
33. Wolbold R., Klein K., Burk O., Nussler A.K., Neuhaus P., Eichelbaum M., Schwab M., and Zanger U.M. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38 (2003) 978-988
34. Wong I.C.K., Mawer G.E., and Sander J.W.A.S. Factors influencing the incidence of lamotrigine-related skin rash. Ann. Pharmacother. 33 (1999) 1037-1042
35. Wrighton S.A., and Stevens J.C. The human hepatic cytochrome P450 involved in drug metabolism. Crit. Rev. Toxicol. 22 (1992) 1-21
36. Zimmerman H.J. Drug-induced liver disease. Clin. Liver Dis. 4 (2000) 73-96 vi